Menu

Sustainability And Sterility Are Incompatible In MedTech

/ Knowledge & Resources / By

❌ The myth:

The myth frames sterility assurance and environmental performance as a trade-off. Choose one, sacrifice the other. It casts single-use devices as the only defensible option for infection control. It dismisses reprocessing, refurbishment and circular design as mere compromises.

Many assume that infection control demands single use. Anything reusable or recycled seems to add risk. On this logic, sustainability and sterility sit on opposite ends of the same scale. MedTech has no real choice but to keep producing disposable devices at volume.

The regulatory and industry evidence from 2025 and 2026 tells a more complicated story.

✅ The reality:

Three developments challenge this framing directly.

Reprocessing Policy Momentum

Article 17 of the MDR already permits reprocessing of single-use devices under strict conditions. Momentum is building to formalise this further. Denmark legalised reprocessing of single-use labelled devices from January 2025. It followed the path Germany and the Netherlands had already set. A proposed MDR amendment would introduce EU-wide harmonised rules. It would also add a new category, full refurbishing, replacing the more limited term remanufacturing that notified bodies currently use.

Circularity Pilots Prove Feasibility

Mölnlycke completed a closed-loop recycling pilot in 2025. It chemically recycled post-consumer operating room waste into new surgical drapes. The industry has long treated surgical drapes as a fixed single-use item, precisely because of infection control requirements. Manufacturers increasingly refurbish and redeploy high-value capital equipment, such as MRI and ultrasound systems, rather than replace it. This extends service life without compromising performance.

Industry Calls For Coherence

MedTech Europe’s recommendations for the EU Circular Economy Act call for alignment. They ask for consistency between Green Deal legislation and the sector-specific MDR and IVDR framework. The two regimes do not currently define terms like reprocessing and refurbishment consistently. The ask is regulatory clarity, not lower standards. Manufacturers want to validate circularity to the same safety bar as any other process.

The Structural Gaps

Three gaps explain why circularity remains the exception rather than the default.

Definitional Gap

The MDR, national law and Circular Economy Act proposals use inconsistent terms. Reprocessing, remanufacturing, refurbishment and full refurbishing each mean something different depending on the source. Manufacturers cannot build a compliant sustainability strategy against terms that shift by jurisdiction.

Regulatory Gap

The EU still has no centralised reprocessing regime. Germany, the Netherlands and Denmark permit it under national rules. Other member states do not. This leaves manufacturers and health institutions to navigate a patchwork rather than a single pathway.

Validation Gap

Demonstrating equivalence is a genuine technical undertaking. A reprocessed, refurbished or recycled device must meet the same sterility assurance level as new. It must also meet the same performance requirements. This demands the same rigour as original certification, applied to a process most quality systems did not originally support.

Where EUMEDIQ And AIMEDIQ Fit

EUMEDIQ’s Role

Closing these gaps is a regulatory affairs problem before it is an engineering one. EUMEDIQ supports manufacturers assessing reprocessing, refurbishment and circular design pathways. We assess these pathways against MDR Article 17, applicable Common Specifications, and national rules. Our gap analyses identify where a sustainability initiative would or would not currently hold up under audit.

AIMEDIQ’s Role

AIMEDIQ tracks the fast-moving legislative side of this picture. This includes Circular Economy Act developments, MDR reform proposals and national reprocessing rules. Every output links back to its source document. Regulators are still finalising both the terminology and the rules on this topic. A current, traceable reference point matters as much as the initial assessment.

Bottom Line

Sustainability and sterility are not opposing forces. Regulatory fragmentation is the real obstacle, not physics or patient safety. Manufacturers who invest now in understanding reprocessing pathways, refurbishment routes and the emerging Circular Economy Act can act quickly. They will not need to start from zero once the rules solidify.

Sources